Synthesis and Anti-inflammatory Properties of 1α,25-Dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a Hypocalcemic, Stable Metabolite of 1α,25-Dihydroxy-16-ene-20-cyclopropyl-vitamin D3

被引:37
作者
Laverny, Gilles [1 ]
Penna, Giuseppe [1 ]
Uskokovic, Milan [2 ]
Marczak, Stanislaw [2 ]
Maehr, Hubert [2 ]
Jankowski, Pawel [2 ]
Ceailles, Caroline [3 ]
Vouros, Paul [3 ]
Smith, Brenden [4 ]
Robinson, Matthew [4 ]
Reddy, G. Satyanarayana [4 ,5 ]
Adorini, Luciano [1 ]
机构
[1] BioXell, I-20132 Milan, Italy
[2] BioXell Inc, Nutley, NJ 07110 USA
[3] Northeastern Univ, Dept Chem, Barnett Inst, Boston, MA 02115 USA
[4] Epimer LLC, Providence, RI 02906 USA
[5] Brown Univ, Dept Chem, Providence, RI 02912 USA
关键词
VITAMIN-D-RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3; ANALOG; INHIBITION; GROWTH; PARENT; CELLS;
D O I
10.1021/jm801365a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
1 alpha,25(OH)(2)-16-ene-20-cyclopropyl-vitamin D-3 (13) is several fold more potent than the natural hormone 1 alpha,25-dihydroxyvitamin D-3 (1) as an anti-infilammatory agent. Here, we have further analyzed the anti-inflammatory properties of 13, confirming it as the most potent analogue tested within this family. We then determined the structures of all the natural metabolites of 13, including the 24-oxo metabolite 14, and carried out its synthesis. A comparison of 13 with 14 showed a similar induction of the primary VDR target genes CYP24A1 and CAMP and comparable anti-inflammatory properties as revealed by a similar inhibition of TNF-alpha, IL-12/23p40, IL-6, and IFN-gamma production. Interestingly, 14 displays a 3-fold lower calcemic activity in vivo compared to 13. Collectively, these findings indicate that the strong potency of 13 can be explained by the accumulation of its stable 24-oxo metabolite, which shows immunoregulatory and anti-inflammatory properties superimposable, to those exerted by 13 itself.
引用
收藏
页码:2204 / 2213
页数:10
相关论文
共 42 条
[21]   Synthesis and biological activities of new 1α,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain [J].
Shimizu, Masato ;
Miyamoto, Yukiko ;
Kobayashi, Emi ;
Shimazaki, Mika ;
Yamamoto, Keiko ;
Reischl, Wolfgang ;
Yamada, Sachiko .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (12) :4277-4294
[22]   New derivative of 1α,25-dihydroxy-19-norvitamin D3 with 3′-alkoxypropylidene moiety at C-2:: synthesis, biological activity and conformational analysis [J].
Glebocka, A ;
Sicinski, RR ;
DeLuca, HF .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5) :25-30
[23]   Clonal differences in expression of 25-hydroxyvitamin D3-1α-hydroxylase, of 25-hydroxyvitamin D3-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells:: Effects of epidermal growth factor and 1α,25-dihydroxyvitamin D3 [J].
Bareis, P ;
Kállay, E ;
Bischof, MG ;
Bises, G ;
Hofer, H ;
Pötzi, C ;
Manhardt, T ;
Bland, R ;
Cross, HS .
EXPERIMENTAL CELL RESEARCH, 2002, 276 (02) :320-327
[24]   Antiproliferative effects of the biologically active metabolite of vitamin D3 (1,25 [OH](2) D-3) on head and neck squamous cell carcinoma cell lines [J].
Kornfehl, J ;
Formanek, M ;
Temmel, A ;
Knerer, B ;
Willheim, M .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1996, 253 (06) :341-344
[25]   Synthesis of 2α- and 2β-(3-hydroxypropyl)-7,8-cis-14-epi-1α,25-dihydroxy-19-norvitamin D3 and their biological activity [J].
Sawada, Daisuke ;
Ochiai, Eiji ;
Takeuchi, Akiko ;
Kakuda, Shinji ;
Kamimura-Takimoto, Midori ;
Kawagoe, Fumihiro ;
Kittaka, Atsushi .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 173 :79-82
[26]   Synthesis of a 1α-C-methyl analogue of 25-hydroxyvitamin D3: interaction with a mutant vitamin D receptor Arg274Leu [J].
Honzawa, Shinobu ;
Takahashi, Naoyuki ;
Yamashita, Atsushi ;
Sugiura, Takayuki ;
Kurihara, Masaaki ;
Arai, Midori A. ;
Kato, Shigeaki ;
Kittaka, Atsushi .
TETRAHEDRON, 2009, 65 (34) :7135-7145
[27]   Effects of 1 alpha,25-dihydroxy-16ene, 23yne-vitamin D-3 on osteoblastic function in human osteosarcoma SaOS-2 cells: Differentiation-stage dependence and modulation by 17-beta estradiol [J].
Rao, LG ;
Sutherland, MK ;
Reddy, GS ;
SiuCaldera, ML ;
Uskokovic, MR ;
Murray, TM .
BONE, 1996, 19 (06) :621-627
[28]   1, 25-dihydroxy-vitamin D3 with tumor necrosis factor-alpha protects against rheumatoid arthritis by promoting p53 acetylation-mediated apoptosis via Sirt1 in synoviocytes [J].
Gu, Xin ;
Gu, Bingjie ;
Lv, Xianhui ;
Yu, Zhenzhen ;
Wang, Rong ;
Zhou, Xiaoli ;
Qiao, Wanxin ;
Mao, Zhiyuan ;
Zuo, Guoping ;
Li, Qing ;
Miao, Dengshun ;
Jin, Jianliang .
CELL DEATH & DISEASE, 2016, 7 :e2423-e2423
[29]   Anti-inflammatory effect of 1α,25-dihydroxyvitamin D3 in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease [J].
Suzuki, Yasuo ;
Ichiyama, Takashi ;
Ohsaki, Ayami ;
Hasegawa, Shunji ;
Shiraishi, Masahiro ;
Furukawa, Susumu .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2009, 113 (1-2) :134-138
[30]   1α,25-Dihydroxyvitamin D3 restrains stem cell-like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44 [J].
Ji, Mintao ;
Liu, Lizhi ;
Hou, Yongfeng ;
Li, Bingyan .
ONCOLOGY REPORTS, 2019, 41 (06) :3393-3403